IL155992A0 - Pharmaceutical compositions for the oral delivery of pharmacologically active agents - Google Patents

Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Info

Publication number: IL155992A0
Authority: IL; Israel
Prior art keywords: pharmacologically active; active agents; pharmaceutical compositions; oral delivery; delivery
Prior art date: 2000-12-06

Application number

IL15599201A

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-06

Filing date

2001-12-05

Publication date

2003-12-23

2001-12-05 Application filed by Novartis Ag filed Critical Novartis Ag

2003-12-23 Publication of IL155992A0 publication Critical patent/IL155992A0/xx

Links

239000013543 active substance Substances 0.000 title abstract 5
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
229960000913 crospovidone Drugs 0.000 abstract 1
229940124447 delivery agent Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
229940069328 povidone Drugs 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL15599201A 2000-12-06 2001-12-05 Pharmaceutical compositions for the oral delivery of pharmacologically active agents IL155992A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25172900P	2000-12-06	2000-12-06
PCT/EP2001/014294 WO2002045754A2 (en)	2000-12-06	2001-12-05	Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Publications (1)

Publication Number	Publication Date
IL155992A0 true IL155992A0 (en)	2003-12-23

Family

ID=22953160

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15599201A IL155992A0 (en)	2000-12-06	2001-12-05	Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IL155992A IL155992A (en)	2000-12-06	2003-05-19	Pharmacological preparations of pharmacologically active substances for oral administration

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL155992A IL155992A (en)	2000-12-06	2003-05-19	Pharmacological preparations of pharmacologically active substances for oral administration

Country Status (26)

Country	Link
US (1)	US7049283B2 (no)
EP (1)	EP1341526B1 (no)
JP (2)	JP4898078B2 (no)
KR (1)	KR100847695B1 (no)
CN (1)	CN1304048C (no)
AT (1)	ATE513541T1 (no)
AU (2)	AU2002234547B2 (no)
BR (2)	BRPI0115965B1 (no)
CA (1)	CA2436599C (no)
CY (1)	CY1112562T1 (no)
CZ (1)	CZ305418B6 (no)
DK (1)	DK1341526T3 (no)
EC (1)	ECSP034639A (no)
ES (1)	ES2367009T3 (no)
HU (1)	HU230632B1 (no)
IL (2)	IL155992A0 (no)
MX (1)	MXPA03005096A (no)
NO (1)	NO332936B1 (no)
NZ (1)	NZ526196A (no)
PL (1)	PL209703B1 (no)
PT (1)	PT1341526E (no)
RU (1)	RU2287999C2 (no)
SI (1)	SI1341526T1 (no)
SK (1)	SK287613B6 (no)
WO (1)	WO2002045754A2 (no)
ZA (1)	ZA200304295B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ534409A (en)	1999-04-05	2006-03-31	Emisphere Tech Inc	Disodium salts, monohydrates, and ethanol solvates for delivering active agents
KR101320817B1 (ko) *	2001-06-01	2013-10-21	노파르티스 아게	부갑상선 호르몬 및 칼시토닌의 경구 투여
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) *	2002-07-17	2004-03-01	Novartis Ag	Use of organic compounds
AR040737A1 (es) *	2002-08-01	2005-04-20	Novartis Ag	Administracion oral de calcitonina
PT1603553E (pt) *	2003-03-17	2012-02-03	Japan Tobacco Inc	Composições farmacêuticas de inibidores de cetp
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
BRPI0412458A (pt) *	2003-07-11	2006-10-17	Novartis Ag	composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
JP4716987B2 (ja) *	2003-07-23	2011-07-06	ノバルティスアーゲー	骨関節症におけるカルシトニンの使用
ES2401769T5 (es) *	2003-09-12	2020-07-01	Amgen Inc	Formulación de disolución rápida de cinacalcet HCl
AU2005244986B2 (en) *	2004-05-19	2011-01-27	Emisphere Technologies, Inc.	Topical cromolyn formulations
GB0422644D0 (en) *	2004-10-12	2004-11-10	Novartis Ag	Organic compounds
GB0427603D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
US20080153779A1 (en) *	2005-02-01	2008-06-26	Jun Liao	Gastric Retention and Controlled Release Delivery System
WO2007005995A2 (en) *	2005-07-05	2007-01-11	Emisphere Technologies, Inc.	Compositions for buccal delivery of human growth hormone
CN101627011A (zh)	2005-09-19	2010-01-13	爱密斯菲尔科技公司	N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
CN101309674A (zh) *	2005-11-17	2008-11-19	诺瓦提斯公司	药物组合物
WO2007095716A1 (en) *	2006-02-23	2007-08-30	Iomedix Sleep International Srl	Compositions and methods for the induction and maintenance of quality sleep
WO2008021088A2 (en) *	2006-08-08	2008-02-21	The Regents Of The University Of Californina	Salicylanilides enhance oral delivery of therapeutic peptides
CA2661521C (en) *	2006-08-31	2016-04-12	Novartis Ag	Pharmaceutical compositions comprising hgh for oral delivery
CA2572004A1 (en) *	2006-12-08	2008-06-08	Bernard Charles Sherman	Tablets comprising entacapone and crospovidone
KR20150091536A (ko) *	2007-03-02	2015-08-11	노파르티스 아게	칼시토닌의 경구 투여
PL2215047T3 (pl)	2007-11-02	2014-05-30	Emisphere Tech Inc	Sposób leczenia niedoborów witaminy b12
JP5740689B2 (ja) *	2008-08-18	2015-06-24	エンテラバイオエルティーディー．	タンパク質の経口投与用の方法および組成物
KR101673042B1 (ko) *	2009-03-12	2016-11-04	키바이오사이언스 아게	당뇨병 및 대사 증후군의 치료
WO2011156563A2 (en) *	2010-06-09	2011-12-15	Emisphere Technologies, Inc.	Oral iron deficiency therapy
PL2651398T3 (pl)	2010-12-16	2018-05-30	Novo Nordisk A/S	Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en)	2011-04-12	2017-02-06	Novo Nordisk As	Double-acylated GLP-1 derivatives
HUE042757T2 (hu)	2012-03-22	2019-07-29	Novo Nordisk As	Szállító szert tartalmazó készítmények és elõállításuk
PL3542790T3 (pl)	2012-03-22	2024-02-26	Novo Nordisk A/S	Kompozycje zawierające substancję dostarczającą i ich przygotowanie
EP4324475A1 (en)	2012-03-22	2024-02-21	Novo Nordisk A/S	Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko)	2013-05-02	2021-07-08	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
CN104961687B (zh) *	2015-06-03	2017-07-25	苏州维泰生物技术有限公司	1,2‑二嗪衍生物及其制剂、用途
SG11201707145QA (en) *	2015-07-08	2017-10-30	Univ Sungkyunkwan Res & Bus	Pyrrolidine carboxamido derivatives and methods for preparing and using the same
WO2017064538A1 (en) *	2015-10-16	2017-04-20	Nobel Ilac Sanayii Ve Ticaret A.S.	Pharmaceutical compositions of nilotinib hydrochloride
CN107080739A (zh) *	2017-04-17	2017-08-22	深圳市泛谷药业股份有限公司	一种用于口服给药的固体快速释放布南色林片及其制备方法
WO2019149880A1 (en)	2018-02-02	2019-08-08	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
JP2021054781A (ja) *	2019-09-26	2021-04-08	デボンエルエス，リミテッド	共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) *	2020-12-29	2021-09-13	대봉엘에스 주식회사	에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5015633A (en)	1987-04-27	1991-05-14	E. R. Squibb & Sons, Inc.	Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en)	1987-09-15	1998-05-26	Novartis Corporation	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en)	1989-02-06	1991-03-26	Rorer Pharmaceutical Corp.	Calcitonin suppository formulations
IT1238072B (it)	1990-01-19	1993-07-03	Sclavo Spa	Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) *	1991-06-25	1993-01-08	Pioneer Electron Corp	光記録媒体
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
DE69520292T2 (de)	1994-12-14	2001-06-13	Bioglan Ireland (R & D) Ltd., Dublin	Pharmazeutische zubereitung zur direktverpressung
BR9604880A (pt) *	1995-03-31	1998-05-19	Emisphere Tech Inc	Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en)	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5912014A (en) *	1996-03-15	1999-06-15	Unigene Laboratories, Inc.	Oral salmon calcitonin pharmaceutical products
US5972381A (en)	1996-06-28	1999-10-26	Schering Corporation	Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (en) *	1996-10-31	1999-01-07	Takeda Chemical Industries, Ltd.	Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5773647A (en)	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
CA2319680C (en)	1997-02-07	2010-04-20	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
AU750539B2 (en)	1998-03-16	2002-07-18	Novartis Ag	Aerosolized active agent delivery
WO2000057857A1 (en)	1999-03-25	2000-10-05	Yuhan Corporation	Rapidly disintegrable tablet for oral administration
AU4218400A (en) *	1999-04-05	2000-10-23	Emisphere Technologies, Inc.	Lyophilized solid dosage forms and methods of making
NZ534409A (en)	1999-04-05	2006-03-31	Emisphere Tech Inc	Disodium salts, monohydrates, and ethanol solvates for delivering active agents

2001
- 2001-12-04 US US10/006,311 patent/US7049283B2/en not_active Expired - Fee Related
- 2001-12-05 PL PL362247A patent/PL209703B1/pl unknown
- 2001-12-05 AT AT01985368T patent/ATE513541T1/de active
- 2001-12-05 BR BRPI0115965-8A patent/BRPI0115965B1/pt unknown
- 2001-12-05 PT PT01985368T patent/PT1341526E/pt unknown
- 2001-12-05 HU HU0302319A patent/HU230632B1/hu not_active IP Right Cessation
- 2001-12-05 CA CA2436599A patent/CA2436599C/en not_active Expired - Fee Related
- 2001-12-05 AU AU2002234547A patent/AU2002234547B2/en not_active Ceased
- 2001-12-05 WO PCT/EP2001/014294 patent/WO2002045754A2/en not_active Ceased
- 2001-12-05 ES ES01985368T patent/ES2367009T3/es not_active Expired - Lifetime
- 2001-12-05 CN CNB018201423A patent/CN1304048C/zh not_active Expired - Fee Related
- 2001-12-05 SI SI200130999T patent/SI1341526T1/sl unknown
- 2001-12-05 EP EP01985368A patent/EP1341526B1/en not_active Expired - Lifetime
- 2001-12-05 JP JP2002547536A patent/JP4898078B2/ja not_active Expired - Fee Related
- 2001-12-05 KR KR1020037007098A patent/KR100847695B1/ko not_active Expired - Fee Related
- 2001-12-05 MX MXPA03005096A patent/MXPA03005096A/es active IP Right Grant
- 2001-12-05 AU AU3454702A patent/AU3454702A/xx active Pending
- 2001-12-05 BR BR0115965-8A patent/BR0115965A/pt not_active IP Right Cessation
- 2001-12-05 RU RU2003119545/15A patent/RU2287999C2/ru not_active IP Right Cessation
- 2001-12-05 CZ CZ2003-1566A patent/CZ305418B6/cs not_active IP Right Cessation
- 2001-12-05 SK SK688-2003A patent/SK287613B6/sk not_active IP Right Cessation
- 2001-12-05 IL IL15599201A patent/IL155992A0/xx active IP Right Grant
- 2001-12-05 NZ NZ526196A patent/NZ526196A/en not_active IP Right Cessation
- 2001-12-05 DK DK01985368.8T patent/DK1341526T3/da active
2003
- 2003-05-19 IL IL155992A patent/IL155992A/en not_active IP Right Cessation
- 2003-06-02 ZA ZA200304295A patent/ZA200304295B/en unknown
- 2003-06-03 NO NO20032511A patent/NO332936B1/no not_active IP Right Cessation
- 2003-06-04 EC EC2003004639A patent/ECSP034639A/es unknown
2009
- 2009-04-13 JP JP2009097262A patent/JP2009185052A/ja not_active Withdrawn
2011
- 2011-08-09 CY CY20111100759T patent/CY1112562T1/el unknown

Also Published As

Publication number	Publication date
PL362247A1 (en)	2004-10-18
CY1112562T1 (el)	2016-02-10
EP1341526A2 (en)	2003-09-10
ES2367009T3 (es)	2011-10-27
SK6882003A3 (en)	2004-01-08
WO2002045754A2 (en)	2002-06-13
HUP0302319A2 (hu)	2003-11-28
JP2004515480A (ja)	2004-05-27
JP2009185052A (ja)	2009-08-20
HUP0302319A3 (en)	2013-04-29
NZ526196A (en)	2005-01-28
HK1059565A1 (en)	2004-07-09
ATE513541T1 (de)	2011-07-15
PT1341526E (pt)	2011-09-01
KR20040018309A (ko)	2004-03-03
BRPI0115965B1 (pt)	2017-09-26
CN1304048C (zh)	2007-03-14
SK287613B6 (sk)	2011-04-05
NO332936B1 (no)	2013-02-04
RU2287999C2 (ru)	2006-11-27
NO20032511D0 (no)	2003-06-03
HU230632B1 (hu)	2017-05-29
MXPA03005096A (es)	2003-09-05
ZA200304295B (en)	2004-05-10
AU2002234547B2 (en)	2005-03-24
KR100847695B1 (ko)	2008-07-23
CZ20031566A3 (cs)	2003-09-17
US20020123459A1 (en)	2002-09-05
JP4898078B2 (ja)	2012-03-14
ECSP034639A (es)	2003-07-25
PL209703B1 (pl)	2011-10-31
SI1341526T1 (sl)	2011-10-28
CZ305418B6 (cs)	2015-09-09
WO2002045754A3 (en)	2003-01-03
AU3454702A (en)	2002-06-18
IL155992A (en)	2008-04-13
NO20032511L (no)	2003-06-03
CA2436599C (en)	2011-01-25
CA2436599A1 (en)	2002-06-13
DK1341526T3 (da)	2011-10-03
EP1341526B1 (en)	2011-06-22
BR0115965A (pt)	2003-10-28
US7049283B2 (en)	2006-05-23
CN1479612A (zh)	2004-03-03

Legal Events

Date	Code	Title	Description
2008-11-27	FF	Patent granted
2008-12-29	KB	Patent renewed

Publication	Publication Date	Title
AU3454702A (en)	2002-06-18	Pharmaceutical compositions for the oral delivery of pharmacologically active agents
PT1651248E (pt)	2009-11-10	Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
ITMI20001173A0 (it)	2000-05-26	Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
EP1392241A4 (en)	2006-01-25	SYSTEM FOR THE OSMOTIC RELEASE OF PHARMACEUTIC EFFECTIVENESS
PL348734A1 (en)	2002-06-03	New sustained release oral formulations
GEP20074047B (en)	2007-02-26	Pramipexole once-daily dosage form
YU68199A (sh)	2002-06-19	Farmaceutske formulacije koje sadrže vorikonazol
AU2001283563A1 (en)	2002-02-25	Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
IL166561A0 (en)	2006-01-15	Pharmaceutical compositions
NZ527157A (en)	2005-04-29	Compositions for delivering bisphosphonates
IL157741A0 (en)	2004-03-28	Pharmaceutical compositions containing an antihyperplastic active agent
IL163552A (en)	2010-11-30	Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
IS6263A (is)	2002-02-08	Lyfjasamsetningar, sem innihalda trípeptíð
MXPA03010761A (es)	2004-03-02	Combinaciones farmaceuticas.
IL151909A0 (en)	2003-04-10	Peptide conjugates for drug delivery
IL157540A0 (en)	2004-03-28	N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
WO2003041656A3 (en)	2003-10-23	Soluble drug extended release system
HUP0303860A3 (en)	2005-05-30	A pharmaceutical tablet having a high active ingredient
BR0114395A (pt)	2005-08-16	Composição farmacêutica para administração por suprimento via oral
MY128759A (en)	2007-02-28	Oral controlled release formulations
MY136370A (en)	2008-09-30	Oxazolidinone tablet formulation
MXPA01008348A (es)	2004-03-19	Microcapsulas para la liberacion prolongada de farmacos.
AU5654701A (en)	2001-11-26	Drug delivery mask
DE69904020D1 (de)	2003-01-02	Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
WO2005062722A3 (en)	2005-09-22	Fexofenadine containing pharmaceutical formulation